抗菌药物敏感性测试市场－全球产业规模、份额、趋势、机会及预测（按产品、技术、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球抗生素敏感性测试市场预计将从 2025 年的 45.2 亿美元成长到 2031 年的 61.3 亿美元，复合年增长率为 5.21%。

此细分市场以研发和供应用于评估特定抗生素对致病微生物疗效的诊断方法和仪器为特征。推动该市场发展的主要因素是全球感染疾病负担日益加重，以及为维持现有疗法的有效性而强制推行抗生素倡议。此外，临床上迫切需要快速诊断结果以促进患者康復并缩短住院时间，也进一步刺激了这项需求。

然而，市场成长面临许多障碍，包括自动化药敏试验平台的高昂成本以及复杂的核准法规结构。这些财务和程序上的障碍往往会阻碍其推广应用，尤其是在医疗资源匮乏的环境中。国际药品製造商协会联合会（IFPMA）在2025年强调了治疗领域的不稳定性。该组织指出，2017年至2023年间，仅有10种新的抗生素或复方製剂获得了严格的监管核准，并强调需要进行严格的测试才能有效控制抗药性。

市场驱动因素

全球抗菌药物抗药性（AMR）的日益严重是全球抗菌药物敏感性检测市场的主要驱动因素，也因此需要精准的诊断设备来指导有效的治疗。随着细菌病原体不断产生对标准药物的抗药性，依赖经验处方变得风险重重，因此，在严重病例中，进行药敏试验对于避免治疗失败至关重要。抗药性细菌的激增促使医疗系统越来越依赖先进的检测基础设施来改善药物管理和患者预后。世界卫生组织（WHO）于2025年10月发布的《2025年全球抗生素抗药性监测报告》指出，在2018年至2023年间，超过40%的受监测病原体-抗生素组合的抗药性有所增加，凸显了依赖准确药敏资料的重要性。

同时，市场成长主要得益于自动化、高通量检测系统的发展，这些系统满足了检查室对速度和营运效率的需求。现代微生物检查室正迅速从劳动密集的手动技术转向利用人工智慧的全自动系统，这些系统能够提供更快、更标准化的结果，并在不增加人员的情况下实现大量检体处理。这种向自动化的转变体现在产业的强劲业绩中。例如，生物梅里埃公司在2025年3月发布的「2024年财务表现」报告中指出，2024年微生物业务收入成长了8.3%，这主要得益于试剂销售量的成长和自动化解决方案的广泛应用。支持这些创新的生态系统也在日趋成熟，CARB-X的2025年报告就证明了这一点。该报告指出，其目标产品的三款产品（包括两款新型诊断产品）已成功上市，证明了有效研发的成效。

市场挑战

诊断产业面临的重大经济和监管障碍正直接限制全球抗菌药物敏感性检测市场的成长。製造商面临日益复杂的核准流程，尤其是自动化系统的审批流程，而合规成本也呈指数级增长。这种监管负担导致研发资金被抽调，并有效地阻碍了创新诊断设备的开发。因此，许多公司被迫推迟产品上市或完全退出某些地区市场，这限制了关键的敏感性检测解决方案在医疗机构中的广泛应用，而对抗抗药性在这些机构中至关重要。

近期行业数据显示，遵循成本之高昂印证了市场活动的下滑。据欧洲医疗技术协会（MedTech Europe）称，到2025年，新监管标准下体外诊断产品的认证和维修成本将比先前的指令增加高达100%。该协会还指出，这些壁垒导致选择欧盟作为其主要上市区域的主要製造商数量下降了40%。这些高准入门槛直接削弱了新型抗菌药物敏感性检测的商业性可行性，并阻碍了整体市场成长。

市场趋势

无培养分子检测技术的整合正在从根本上改变市场格局，它无需耗时的培养程序即可直接从临床检体中识别抗药性基因。这种向基因型分析的转变使临床医生能够在数小时内而非数天内检测到特定的抗药性标记物，例如mecA和vanA，从而显着加快脓毒症和复杂血流感染疾病的标靶治疗。这些先进诊断技术的商业性成功已从近期的产业表现中得到印证。根据生物梅里埃公司于2025年3月发布的2024年财务业绩报告，该公司包含快速血培养鑑定检测的BIOFIRE非呼吸道病原体检测组合在2024年的销售额增长了17%，凸显了临床对快速分子检测在严重感染疾病管理中日益增长的依赖性。

同时，照护现场（POC）解决方案的兴起正在推动抗菌药物敏感性检测的去中心化，将关键分析从中心检查室转移到患者床边。这一趋势的驱动力源于急诊和门诊环境中对即时检测结果的迫切需求，旨在减少不必要的院前抗生素处方，并促进合理用药。这种去中心化基础设施的覆盖范围正在迅速扩大，成熟的分子平台正利用其大规模的用户基础部署抗药性检测。例如，丹纳赫公司在其2025年1月发布的「2024年第四季补充收益资讯」中报告称，其Cefeed部门仅在第四季度就实现了约5.5亿美元的呼吸系统业务收入，这表明快速诊断检测拥有巨大的营运能力，足以支持其更广泛地应用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球抗菌药物敏感性检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（手动测试{MIC试纸、药敏试验纸片、药敏试验板}、自动化设备、耗材及培养基）
  • 依检测方法（自动AST、Etest、稀释法、纸锭扩散法等）
  • 依应用领域（药物研发、药敏试验等）
  • 依最终用户（医院、诊断检查室、生技/製药公司、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美抗菌药物敏感性检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲抗菌药物敏感性检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区抗菌药物敏感性检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲抗菌药物敏感性检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美抗菌药物敏感性检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球抗菌药物敏感性检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bio-Rad Laboratories Inc.
• Merck & Co., Inc.
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• bioMerieux SA
• Becton, Dickinson and Company
• ELITech Group SAS
• F. Hoffmann-La Roche Ltd.
• Accelerate Diagnostics, Inc.
• HiMedia Laboratories Private Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Antimicrobial Susceptibility Testing Market is projected to expand from USD 4.52 Billion in 2025 to USD 6.13 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 5.21%. This sector is characterized by the creation and supply of diagnostic methods and equipment designed to evaluate how effectively specific antimicrobial drugs work against pathogenic microorganisms. A key factor fueling this market is the rising global burden of infectious diseases, alongside the essential requirement for antimicrobial stewardship initiatives aimed at maintaining the effectiveness of current treatments. This demand is intensified by the urgent necessity for quick diagnostic results in clinical environments to enhance patient recovery and decrease the duration of hospitalizations.

However, market growth faces substantial obstacles due to the significant expenses linked to automated susceptibility testing platforms and the intricate regulatory frameworks required for their approval. These financial and procedural hurdles frequently restrict adoption, especially within healthcare settings facing resource limitations. The precarious nature of the therapeutic landscape was emphasized by the International Federation of Pharmaceutical Manufacturers and Associations in 2025, which noted that only 10 new antibiotics or combinations received approval from strict regulatory bodies between 2017 and 2023, highlighting the essential need for precise testing to effectively manage resistance patterns.

Market Driver

The increasing global incidence of antimicrobial resistance (AMR) serves as the main force driving the Global Antimicrobial Susceptibility Testing Market, creating a need for exact diagnostic instruments to direct successful treatment. As bacterial pathogens continue to develop defenses against standard medications, reliance on empirical prescribing has become risky, establishing a critical clinical need for susceptibility profiling to avert treatment failure in severe cases. This surge in resistance compels healthcare systems to depend heavily on sophisticated testing infrastructure to improve stewardship and patient results. In its 'Global Antibiotic Resistance Surveillance Report 2025' released in October 2025, the World Health Organization reported that antibiotic resistance increased in more than 40% of the monitored pathogen-antibiotic combinations between 2018 and 2023, emphasizing the vital reliance on accurate susceptibility data.

Concurrently, the market is receiving a significant boost from developments in automated and high-throughput testing systems that meet laboratory demands for speed and operational efficiency. Modern microbiology labs are quickly moving away from labor-intensive manual techniques toward fully automated systems that employ artificial intelligence to provide faster, standardized outcomes, thereby handling larger sample volumes without increasing staff. This transition to automation is reflected in strong industry performance; for instance, bioMerieux reported in its '2024 Financial Results' in March 2025 that its microbiology sales rose by 8.3% in 2024, largely fueled by higher reagent volumes and the uptake of automated solutions. The ecosystem supporting these innovations is also maturing, as evidenced by CARB-X in 2025, which noted that three supported products, including two new diagnostics, successfully entered the market, demonstrating effective R&D translation.

Market Challenge

The significant economic and regulatory hurdles present in the diagnostic industry are directly limiting the growth of the Global Antimicrobial Susceptibility Testing Market. As manufacturers encounter increasingly intricate approval processes, especially for automated systems, the funds needed for compliance have escalated drastically. This regulatory burden shifts capital away from research and development, effectively halting the creation of innovative diagnostic instruments. As a result, many firms are compelled to postpone product introductions or exit certain regional markets altogether, restricting the reach of critical susceptibility testing solutions in healthcare environments where they are most essential for fighting resistance.

Recent industry data regarding the severity of these compliance expenses confirms this reduction in market activity. According to MedTech Europe in 2025, the costs for certification and maintenance of in vitro diagnostics under new regulatory standards have risen by as much as 100% compared to earlier directives. Additionally, the association noted that the selection of the European Union as a primary launch region declined by 40% among major manufacturers because of these obstacles. Such high barriers to entry directly diminish the commercial feasibility of new antimicrobial susceptibility tests, thereby impeding the overall growth of the market.

Market Trends

The integration of culture-independent molecular testing techniques is fundamentally transforming the market by eliminating lengthy culture procedures to identify resistance genes directly from clinical samples. This move toward genotypic profiling enables clinicians to detect specific resistance markers, such as mecA or vanA, within hours instead of days, greatly speeding up targeted treatments for sepsis and complex bloodstream infections. The commercial success of these advanced diagnostics is clear in recent industry results; bioMerieux's '2024 Financial Results' from March 2025 show that sales of the company's BIOFIRE non-respiratory panels, which incorporate rapid blood culture identification assays, grew by 17% in 2024, emphasizing the increasing clinical dependence on rapid molecular testing for managing severe infections.

At the same time, the growth of point-of-care (POC) diagnostic solutions is decentralizing antimicrobial susceptibility testing, shifting critical analysis from central laboratories to the patient's bedside. This trend is fueled by the critical requirement for instant results in emergency and outpatient environments to reduce unnecessary antibiotic prescribing and enhance stewardship prior to hospital admission. The scope of this decentralized infrastructure is expanding rapidly, as established molecular platforms utilize their large installed bases to deploy resistance assays; for example, Danaher reported in its 'Supplemental Earnings Information for the Fourth Quarter 2024' in January 2025 that its Cepheid division achieved roughly $550 million in respiratory revenue during the fourth quarter alone, highlighting the substantial operational capacity available for the wider adoption of rapid diagnostic tests.

Key Market Players

• Bio-Rad Laboratories Inc.
• Merck & Co., Inc.
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• bioMerieux SA
• Becton, Dickinson and Company
• ELITech Group SAS
• F. Hoffmann-La Roche Ltd.
• Accelerate Diagnostics, Inc.
• HiMedia Laboratories Private Limited

Report Scope

In this report, the Global Antimicrobial Susceptibility Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antimicrobial Susceptibility Testing Market, By Product

• Manual Tests {MIC Strips, Susceptibility Testing Disks, Susceptibility Plates}
• Automated Instruments
• Consumables & Media

Antimicrobial Susceptibility Testing Market, By Technique

• Automated AST
• Etest Method
• Dilution
• Disk Diffusion
• Others

Antimicrobial Susceptibility Testing Market, By Application

• Drug Development
• Susceptibility Testing
• Others

Antimicrobial Susceptibility Testing Market, By End User

• Hospitals
• Diagnostic Laboratories
• Biotechnology & Pharmaceutical Companies
• Others

Antimicrobial Susceptibility Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antimicrobial Susceptibility Testing Market.

Available Customizations:

Global Antimicrobial Susceptibility Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antimicrobial Susceptibility Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Manual Tests {MIC Strips, Susceptibility Testing Disks, Susceptibility Plates}, Automated Instruments, Consumables & Media)
  • 5.2.2. By Technique (Automated AST, Etest Method, Dilution, Disk Diffusion, Others)
  • 5.2.3. By Application (Drug Development, Susceptibility Testing, Others)
  • 5.2.4. By End User (Hospitals, Diagnostic Laboratories, Biotechnology & Pharmaceutical Companies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Antimicrobial Susceptibility Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technique
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antimicrobial Susceptibility Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technique
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Antimicrobial Susceptibility Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technique
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Antimicrobial Susceptibility Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technique
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Antimicrobial Susceptibility Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technique
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antimicrobial Susceptibility Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technique
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Antimicrobial Susceptibility Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technique
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Antimicrobial Susceptibility Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technique
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Antimicrobial Susceptibility Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technique
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Antimicrobial Susceptibility Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technique
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Antimicrobial Susceptibility Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technique
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antimicrobial Susceptibility Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technique
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Antimicrobial Susceptibility Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technique
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Antimicrobial Susceptibility Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technique
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Antimicrobial Susceptibility Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technique
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Antimicrobial Susceptibility Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technique
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Antimicrobial Susceptibility Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technique
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Antimicrobial Susceptibility Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technique
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Antimicrobial Susceptibility Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technique
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Antimicrobial Susceptibility Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technique
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Antimicrobial Susceptibility Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technique
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Antimicrobial Susceptibility Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technique
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Antimicrobial Susceptibility Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technique
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Antimicrobial Susceptibility Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technique
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Antimicrobial Susceptibility Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bio-Rad Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Danaher Corporation
• 15.5. bioMerieux SA
• 15.6. Becton, Dickinson and Company
• 15.7. ELITech Group SAS
• 15.8. F. Hoffmann-La Roche Ltd.
• 15.9. Accelerate Diagnostics, Inc.
• 15.10. HiMedia Laboratories Private Limited

16. Strategic Recommendations

17. About Us & Disclaimer